Skip to main content

Table 1 Patient- or Parent-reported functional ability and hrqol parameters in Trial 2

From: PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients

Outcome measure, mean (SD)

Baseline

CAN, N = 177

End of Part 1

CAN, N = 177

End of Part 2

CAN, N = 50

End of Part 2

PBO, N = 50

CHAQ disability score

1.7 (0.8)

0.74 (0.9)

0.5 (0.9)

0.6 (0.8)

Pain (VAS, 0-100 mm)

66.6 (23.3)

20.2 (25.8)

13.6 (26.9)

17.0 (24.2)

CHQ-PF50 phs score

16.1 (14.3)

37.7 (17.2)

43.6 (17.4)

39.0 (18.1)

CHQ-PF50 pss score

41.6 (11.1)

50.7 (11.1)

53.6 (11.3)

52.7 (9.8)

  1. Results are based on patients with both baseline and post-baseline values. N18 years old.